Mobile

phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocrine ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004748-22

phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocrine tumors

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the antitumor activity in terms of objective response rate (RR) of bevacizumab in combination with somatostatin analogue and capecitabine administered on a metronomic schedule.

Critère d'inclusion

  • Patients with Advanced Inoperable Well-Differentiated Neuroendocrine Tumors

Liens